Search results
7 High-Value Blue-Chip Stocks to Boost Your Wealth by 2027
InvestorPlace· 1 hour agoWhile investing, the focus is on the top blue-chip stocks to buy that offer growth with stability....
Pfizer stock price analysis: how PFE became a fallen angel | Invezz
Invezz· 2 days agoPfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19...
Day One targets the growing ADC market with MabCare acquisition
Pharmaceutical Technology via Yahoo Finance· 21 hours agoDay One has entered a licensing agreement for MTX-13, now called DAY301, a novel antibody drug...
Xencor shares target cut by BMO on plamotamab rights By Investing.com
Investing.com· 6 days agoOn Friday, BMO (TSX:BMO) Capital adjusted its outlook for Xencor, Inc. (NASDAQ: NASDAQ:XNCR) shares,...
Clay Siegall-led biotech inks lease for Bothell headquarters - Puget Sound Business Journal
The Business Journals· 2 days agoBiotech company Immunome Inc. (Nasdaq: IMNM) has signed a lease and is moving into a...
Is It Too Late to Buy Pfizer Stock? | The Motley Fool
The Motley Fool· 6 days agoAre Pfizer's (PFE -0.43%) best days behind it? If the stock's critics are to be believed, the answer...
Pfizer to have 8 'blockbuster' cancer drugs by 2030
Becker’s Hospital Review· 6 days ago"With the completion of the Seagen acquisition in 2023, Pfizer has significantly expanded its oncology organization to amplify its efforts to advance new standards of care ...
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 3 days agoPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock was trading at $52 in early June 2022, just before the Fed started ...
How a well-traveled brain cancer drug turned into an $8 million payday for an East Bay firm - San...
The Business Journals· 3 days agoA drug traded between companies for 20 years — and approved by regulators in April to treat brain...
Bright Peak Therapeutics bags $90 million Series C to develop cancer immunotherapies
BioPharma-Reporter· 7 days agoBright Peak’s Series C round was led by Johnson & Johnson Innovation with participation from...
